Five lanes are open. The sixth is a decision, and the recommendation is no.

Why the lane is empty

• Galderma’s cross-section reel: 4,337 engagements, 56.8 per thousand followers — the ceiling in our entire read set.
• Every other brand-owned post we read on Instagram: 12.1 per thousand or below.
• Zero mechanism animations found across all six Ring-1 structural analogs.
• Conexeu’s own site already describes CXU™ as “a temporary structural framework” — the copy exists, the film does not.

The move

1. Commission one 22-second sub-dermal render. One continuous descent, three named layers, ending on host cells populating the lattice.
2. Cut it three ways — 12s, 22s, 45s with CSO narration — and post the same asset across all four channels within one week.
3. Lift stills from the render for slide four of the proof carousel and for the aesthetics page hero. One render, six placements.
4. Legal review at storyboard, not at render lock. The verbs are the risk, not the visuals.

Why the lane is empty

• 81% of providers treating GLP-1 patients use HA fillers — from Allergan Aesthetics’ own 2026 data.
• 67% of facial plastic surgeons report more GLP-1-related requests, a 45% rise on 2024; facial fat grafting up 50% for a second year.
• January 2026 consensus guidance prioritises biostimulators for medication-driven weight loss — provoking collagen, not replacing architecture.
• 63% of these patients had never had a cosmetic treatment before, so no brand owns their vocabulary yet.
• Conexeu’s CEO already articulated this thesis on Stocks to Watch. It earned 33 engagements because it was posted as an off-platform video link to 746 people.

The move

1. Ship the seven-slide carousel in Chapter 02 as the first asset of the quarter, on Instagram and as a LinkedIn PDF document post.
2. Publish the same argument as a /bioregeneration page section with question-shaped H2s, so answer engines can cite it.
3. Run the CSO answering one GLP-1 question per week for six weeks, from her own profile.
4. Never name a competitor product. Argue mechanism classes: occupy, provoke, structure.

Why the lane is empty

• Galderma’s chair, text only, first person: 225 engagements.
• A Wyss scientist, personal video: 190 engagements, 27 comments.
• Conexeu’s three video posts (82 / 33 / 23) all outperform its three text posts (30 / 28 / 11).
• Thought-leader distribution runs roughly 1.6× the engagement rate and 1.7× the click-through of the same content on a company page.
• No company in any ring is doing this systematically.

The move

1. One post a week each from Dr Chavez-Munoz and Dr Pilcher, from their own profiles. Written by them, reviewed by legal, never ghost-written in corporate register.
2. The company page comments on those posts rather than resharing them. A reshare splits the engagement; a comment compounds it.
3. Re-tell the Wake Forest programme in the first person. The text-and-link version earned 30 engagements; the same news told by the person running it is the strongest asset available.
4. Give each of them one owned question. Chavez-Munoz owns architecture and reconstruction; Pilcher owns the clinical and regulatory path.

Why the lane is empty

• 31 macro stills from the NYC shoot, 22 from the North Carolina shoot — drops, pokes, straight pulls, tong tests.
• Material-behaviour video holds attention with no hook and no face, which is exactly what a company with no permitted claims needs.
• Nothing comparable exists anywhere in Ring 1: no competitor is showing the physical behaviour of its matrix.
• It argues the positioning pre-verbally — a material that holds structure on a needle tip looks like architecture without anyone saying so.

The move

1. Cut six clips at 6–12 seconds, one behaviour each, seamless loops, texture audio only.
2. Caption carries the whole information load, including the caution line in the first 125 characters.
3. Ship all six to Reels, and master them 9:16 so the same files travel if the TikTok question in Chapter 06 is ever answered yes.
4. Hold the comparator frames. They are the highest-value and highest-risk images in the vault, and they do not ship without written legal sign-off.

Why the category stays out

• Fair balance does not fit the format. FDA’s character-space guidance still requires risk information inside the same communication as any benefit claim — on short video that means risk overlays held on screen for a defined duration. Through 2026 FDA has issued warning letters aimed specifically at benefit-only social posts and at risk information pushed into the comments.
• The comment section creates a reporting duty. FDA’s May 2025 warning letter to Sprout Pharmaceuticals is reported to state plainly that a comment under a company post describing an adverse reaction triggers reporting obligations — and that declining to monitor does not insulate the company once an employee has seen it. For a device the equivalent duty is Medical Device Reporting. TikTok comment volume is what makes that duty expensive rather than theoretical.
• Platform policy has no slot for an uncleared device. TikTok bars consumer prescription-drug promotion outright and gates medical devices behind market-specific pre-approval and proof of authorisation from the relevant regulator. CXU™ has no authorisation to present.
• The For You page ignores jurisdiction. Algorithmic distribution carries a US-intended post into markets with different promotional regimes. Allergan states an intended audience in its Instagram bio; on TikTok that statement is unenforceable.
• Practitioners are not regulated as manufacturers. That asymmetry is why injectors and med spas own this platform and brands do not. An injector can post a result; the company whose product produced it usually cannot.
• The one genuine opening: unbranded condition and category education — what an extracellular matrix is, why rapid weight loss changes facial structure — with no product named and no device shown. Disease-state education is the established compliant lane, and it happens to be where most of the eight target queries in Chapter 07 actually live.

The move

1. Write the decision down before opening anything. One page: what may be said unbranded, who moderates, how a comment describing a reaction is escalated and logged, who signs off, and what the retention obligation is. If that page cannot be written, the answer is no — and a documented no is a real deliverable.
2. Recommendation for this quarter: do not open a branded account. Send the macro material films and the mechanism cut-downs to Reels instead. Same 9:16 masters, heavily overlapping audience, an account that already exists, and a comment surface small enough to actually moderate at 695 followers.
3. Reserve the handle anyway. Squatting is free and losing @conexeu on the platform is not recoverable.
4. Revisit at 510(k) clearance in wound care. Clearance is what converts this from a compliance problem into a marketing channel, and it is the natural trigger to reopen the question rather than relitigating it quarterly.
5. If leadership wants presence sooner, run it unbranded and comment-restricted, with the moderation and escalation workflow live on day one rather than bolted on after the first incident.

What is currently broken

• No Organization or Corporation node anywhere on the marketing site; no canonical on any page; all twelve public pages share one meta description.
• ir.conexeu.com publishes its own Corporation node with a street address but no ticker, URL, logo, sameAs or identifiers.
• Roughly 40% of information-seeking queries now begin in an AI interface rather than a search engine, and AI Overviews appear on the large majority of healthcare queries.
• Around 44% of LLM citations come from the first 30% of a page, and for commercial queries the overwhelming majority come from pages updated within twelve months.

The move

1. Settle the legal-name string once — SEC EDGAR spells it Conexeu Sciences Inc., no comma — and use it identically in schema, in both social bios, and on every profile.
2. Publish one Organization node on conexeu.com with tickerSymbol, logo, identifier and a sameAs array that includes the LinkedIn and Instagram profiles, then raise the duplicate-node conflict with Equisolve as a vendor ticket.
3. Rewrite the twelve meta descriptions and give the aesthetics vertical a 40–60 word direct answer under a question-shaped H2.
4. Mirror every carousel argument as page text. A slide cannot be cited; a paragraph can.